Novel and potential future therapeutic options in systemic autoimmune diseases

被引：11

作者：

Balogh, Lili ^{[1
,2
,3
]}

Olah, Katalin ^{[1
,2
,3
]}

Santa, Soma ^{[1
,2
,3
]}

Majerhoffer, Nora ^{[1
,2
,3
]}

Nemeth, Tamas ^{[1
,2
,3
,4
,5
]}

机构：

[1] Semmelweis Univ, Dept Physiol, Sch Med, Budapest, Hungary

[2] Hungarian Acad Sci, MTA SE Lendulet Translat Rheumatol Res Grp, Budapest, Hungary

[3] Semmelweis Univ, Budapest, Hungary

[4] Semmelweis Univ, Dept Rheumatol & Clin Immunol, Budapest, Hungary

[5] Semmelweis Univ, Dept Internal Med & Oncol, Budapest, Hungary

来源：

FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷

关键词：

autoimmune disease; pathomechanism; treatment; inhibitor; antibody; clinical trial; PRIMARY SJOGRENS-SYNDROME; DOUBLE-BLIND; LUPUS-ERYTHEMATOSUS; RHEUMATOID-ARTHRITIS; EOSINOPHILIC GRANULOMATOSIS; PHASE-2; TRIAL; EFFICACY; SAFETY; PLACEBO; SCLEROSIS;

D O I：

10.3389/fimmu.2024.1249500

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Autoimmune inflammation is caused by the loss of tolerance to specific self-antigens and can result in organ-specific or systemic disorders. Systemic autoimmune diseases affect a significant portion of the population with an increasing rate of incidence, which means that is essential to have effective therapies to control these chronic disorders. Unfortunately, several patients with systemic autoimmune diseases do not respond at all or just partially respond to available conventional synthetic disease-modifying antirheumatic drugs and targeted therapies. However, during the past few years, some new medications have been approved and can be used in real-life clinical settings. Meanwhile, several new candidates appeared and can offer promising novel treatment options in the future. Here, we summarize the newly available medications and the most encouraging drug candidates in the treatment of systemic lupus erythematosus, rheumatoid arthritis, Sjogren's disease, systemic sclerosis, systemic vasculitis, and autoimmune myositis.

引用

页数：16

共 146 条

[1] Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial [J].

Acharya, Nupoor ;

Sharma, Shefali Khanna ;

Mishra, Debashish ;

Dhooria, Sahajal ;

Dhir, Varun ;

Jain, Sanjay .

RHEUMATOLOGY INTERNATIONAL, 2020, 40 (05) :703-710

[2] Trial of Intravenous Immune Globulin in Dermatomyositis [J].

Aggarwal, R. ;

Charles-Schoeman, C. ;

Schessl, J. ;

Bata-Csorgo, Z. ;

Dimachkie, M. M. ;

Griger, Z. ;

Moiseev, S. ;

Oddis, C. ;

Schiopu, E. ;

Vencovsky, J. ;

Beckmann, I ;

Clodi, E. ;

Bugrova, O. ;

Danko, K. ;

Ernste, F. ;

Goyal, N. A. ;

Heuer, M. ;

Hudson, M. ;

Hussain, Y. M. ;

Karam, C. ;

Magnolo, N. ;

Nelson, R. ;

Pozur, N. ;

Prystupa, L. ;

Sardy, M. ;

Valenzuela, G. ;

van Der Kooi, A. J. ;

Vu, T. ;

Worm, M. ;

Levine, T. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (14) :1264-1278

[3] Use of Rituximab in Systemic Lupus Erythematosus: A Single Center Experience Over 14 Years [J].

Aguiar, R. ;

Araujo, C. ;

Martins-Coelho, G. ;

Isenberg, D. .

ARTHRITIS CARE & RESEARCH, 2017, 69 (02) :257-262

[4] Low-dose interleukin-2 therapy: a promising targeted therapeutic approach for systemic lupus erythematosus [J].

Akbarzadeh, Reza ;

Riemekasten, Gabriela ;

Humrich, Jens Y. .

CURRENT OPINION IN RHEUMATOLOGY, 2023, 35 (02) :98-106

[5] Innate and Adaptive Immunity in Giant Cell Arteritis [J].

Akiyama, Mitsuhiro ;

Ohtsuki, Shozo ;

Berry, Gerald J. ;

Liang, David H. ;

Goronzy, Jorg J. ;

Weyand, Cornelia M. .

FRONTIERS IN IMMUNOLOGY, 2021, 11

[6] The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus [J].

Alexander, Tobias ;

Sarfert, Ramona ;

Klotsche, Jens ;

Kuehl, Anja A. ;

Rubbert-Roth, Andrea ;

Lorenz, Hannes-Martin ;

Rech, Juergen ;

Hoyer, Bimba F. ;

Cheng, Qingyu ;

Waka, Aderajew ;

Taddeo, Adriano ;

Wiesener, Michael ;

Schett, Georg ;

Burmester, Gerd-Ruediger ;

Radbruch, Andreas ;

Hiepe, Falk ;

Voll, Reinhard E. .

ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (07) :1474-1478

[7] Systemic sclerosis [J].

Allanore, Yannick ;

Simms, Robert ;

Distler, Oliver ;

Trojanowska, Maria ;

Pope, Janet ;

Denton, Christopher P. ;

Varga, John .

NATURE REVIEWS DISEASE PRIMERS, 2015, 1

[8] Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial [J].

Armstrong, April W. ;

Gooderham, Melinda ;

Warren, Richard B. ;

Papp, Kim A. ;

Strober, Bruce ;

Thaci, Diamant ;

Morita, Akimichi ;

Szepietowski, Jacek C. ;

Imafuku, Shinichi ;

Colston, Elizabeth ;

Throup, John ;

Kundu, Sudeep ;

Schoenfeld, Steve ;

Linaberry, Misti ;

Banerjee, Subhashis ;

Blauvelt, Andrew .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 88 (01) :29-39

[9] Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study [J].

Bekker, Pirow ;

Dairaghi, Daniel ;

Seitz, Lisa ;

Leleti, Manmohan ;

Wang, Yu ;

Ertl, Linda ;

Baumgart, Trageen ;

Shugarts, Sarah ;

Lohr, Lisa ;

Dang, Ton ;

Miao, Shichang ;

Zeng, Yibin ;

Fan, Pingchen ;

Zhang, Penglie ;

Johnson, Daniel ;

Powers, Jay ;

Jaen, Juan ;

Charo, Israel ;

Schall, Thomas J. .

PLOS ONE, 2016, 11 (10)

[10] Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells [J].

Bergmann, Christina ;

Mueller, Fabian ;

Distler, Joerg H. W. ;

Gyoerfi, Andrea-Hermina ;

Voelkl, Simon ;

Aigner, Michael ;

Kretschmann, Sascha ;

Reimann, Hannah ;

Harrer, Thomas ;

Bayerl, Nadine ;

Boeltz, Sebastian ;

Wirsching, Andreas ;

Taubmann, Jule ;

Roesler, Wolf ;

Spriewald, Bernd ;

Wacker, Jochen ;

Atzinger, Armin ;

Uder, Michael ;

Kuwert, Torsten ;

Mackensen, Andreas ;

Schett, Georg .

ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (08) :1117-1120

← 1 2 3 4 5 6 7 8 9 10 →